Trazimera (Trastuzumab-Qyyp) for Breast Cancer

Overview
Trazimera is approved by the U.S. Food and Drug Administration (FDA) for the treatment of HER2-overexpressing breast cancer. Individuals who are eligible for Trazimera must have breast cancer that overexpresses the HER2 protein. Trazimera is considered a biosimilar to Herceptin (trastuzumab), meaning it is highly similar to the original FDA-approved biological product with no clinically meaningful differences in safety, purity, and potency. Trazimera is also known by its drug name, trastuzumab-qyyp.

Trazimera belongs to the category of monoclonal antibodies that target the HER2 receptor, which is overexpressed in some breast cancers. It works by binding to the HER2 receptors on the surface of cancer cells, thereby inhibiting cell growth and survival, and marking the cells for destruction by the immune system.

How do I take it?
Prescribing information states that Trazimera is administered as an intravenous (IV) infusion. For the adjuvant treatment of HER2-overexpressing breast cancer, an initial dose is administered over a 90-minute IV infusion. This is followed by either a weekly infusion schedule alongside other chemotherapy agents such as paclitaxel or docetaxel or every three weeks without other chemotherapeutic agents, continuing for a total duration of 52 weeks. In metastatic HER2-overexpressing breast cancer, Trazimera is given with an initial 90-minute infusion followed by weekly doses. The drug should be administered exactly as prescribed by a health care provider.

Side effects
Common side effects of Trazimera include headache, diarrhea, nausea, chills, fever, infection, and insomnia. Individuals receiving Trazimera for metastatic breast cancer may also experience additional side effects such as congestive heart failure (a condition where the heart cannot pump blood effectively), cough, and rash.

Rare but serious side effects may include cardiomyopathy (disease of the heart muscle), severe infusion reactions, pulmonary toxicity (lung damage), and embryo-fetal toxicity (harm to an embryo, fetus, or unborn baby). Individuals should be monitored closely for these severe reactions, especially those with a history of heart disease or lung problems.

For more information about this treatment, visit:

Label: Trazimera — Trastuzumab-Qyyp Kit — DailyMed

Trazimera — Drugs.com